BioCryst Pharmaceuticals
BCRX
BCRX
136 hedge funds and large institutions have $473M invested in BioCryst Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 55 increasing their positions, 24 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
18% more funds holding
Funds holding: 115 → 136 (+21)
0.31% less ownership
Funds ownership: 89.41% → 89.1% (-0.31%)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Holders
136
Holding in Top 10
1
Calls
$1.84M
Puts
$570K
Top Buyers
| 1 | +$17.7M | |
| 2 | +$14.7M | |
| 3 | +$13.8M | |
| 4 |
DM
Deerfield Management
New York
|
+$12.4M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$11.8M |
Top Sellers
| 1 | -$8.24M | |
| 2 | -$8.14M | |
| 3 | -$7.76M | |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$6.14M |
| 5 |
Morgan Stanley
New York
|
-$2.55M |